CervoMed is trading 5.87% down at $2.76, continuing weakness after declining 4.56% to $2.93 on August 13, 2026.
- No new company-specific announcement dated August 14 was identified.
- CervoMed’s latest update was its August 10 second-quarter report, which highlighted the need for a strategic partner or additional funding to advance its Phase 3 program.
- The release did not directly link those issues to today’s decline.